Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies

@inproceedings{Allais2013FrovatriptanVO,
  title={Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies},
  author={Gianni Allais and Vincenzo Tullo and Stefano Omboni and Deborha Pezzola and Dario Zava and Chiara Benedetto and Gennaro Bussone},
  booktitle={Neurological Sciences},
  year={2013}
}
Oral contraceptive-induced menstrual migraine (OCMM) is a particularly severe form of migraine triggered by the cyclic hormone withdrawal. To review the efficacy of frovatriptan vs. other triptans, in the acute treatment of OCMM through a pooled analysis of three individual randomized Italian studies. With or without aura migraineurs were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 20 references

a pilot study

  • F Facchinetti, G Allais, +7 authors migraine oral contraceptiveinduced menstrual
  • Gynecol Endocrinol 26:773–779 S86 Neurol Sci
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…